Acquired Company

XOMA Royalty acquired LAVA Therapeutics N.V. on 11/21/2025 for $1.04 per share in cash, plus a non-transferable contingent value right (CVR) per share.

Lava Therapeutics BV, a biotechnology company, is dedicated to developing a portfolio of gamma-delta bispecific T-cell activators (gamma-delta bsTCE) for the treatment of solid tumors and hematologic malignancies based on its platform. The company is headquartered in Utrecht, the Netherlands. Show more

YALELAAN 62, UTRECHT, NETHERLANDS, 3584 CM, Utrecht, 3584 CM, USA

https://www.lavatherapeutics.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

45.77M

52 Wk Range

$0.94 - $1.82

Previous Close

$1.74

Open

$1.74

Volume

N/A

Day Range

$1.74 - $1.74

Enterprise Value

-3.893M

Cash

49.66M

Avg Qtr Burn

-4.868M

Insider Ownership

16.39%

Institutional Own.

27.54%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
PF-08046052 (formerly LAVA-1223) Details Cancer, Solid tumor/s	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-1266 Details Cancer, Hematologic malignancies, Acute myeloid leukemia, Myelodysplastic syndrome	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-1207 Details Solid tumor/s, Cancer, Prostate cancer, Castration-resistant prostate cancer, Prostate disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LAVA-051 ( gamma-delta bsTCE targeting CD1d-expressing tumors) Details Solid tumor/s, Cancer, Chronic lymphocytic leukemia, Acute myeloid leukemia, Multiple myeloma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.